Not Just Weight Loss: The Unexpected Brain Benefits of an Anti-Obesity Drug

Brain Obesity Weight Loss

Researchers at the Max Planck Institute found that obesity, characterized by reduced insulin sensitivity, impairs the brain’s associative learning capability. However, a single dose of the anti-obesity drug liraglutide restored this ability, equalizing brain activity between obese and normal-weight participants.

Liraglutide enhances brain function in individuals with obesity.

For our brain to control our actions, it needs to establish links between different stimuli. For instance, it learns to connect a seemingly harmless visual cue to its potential outcome (like a red-hot hotplate indicating a risk of burning one’s hand). This process helps our brain understand the consequences of interacting with certain stimuli.

Associative learning is the basis for forming neural connections and gives stimuli their motivational force. It is essentially controlled by a brain region called the dopaminergic midbrain. This region has many receptors for the body’s signaling molecules, such as insulin, and can thus adapt our behavior to the physiological needs of our body.

But what happens when the body’s insulin sensitivity is reduced due to obesity? Does this change our brain activity, our ability to learn associations, and thus our behavior? Researchers at the Max Planck Institute for Metabolism Research have now measured how well the learning of associations works in participants with normal body weight (high insulin sensitivity, 30 volunteers) and in participants with obesity (reduced insulin sensitivity, 24 volunteers), and if this learning process is influenced by the anti-obesity drug liraglutide.

Low insulin sensitivity reduces the brain’s ability to associate sensory stimuli.

In the evening, they injected the participants with either the drug liraglutide or a placebo in the evening. Liraglutide is a so-called GLP-1 agonist, which activates the GLP-1 receptor in the body, stimulating insulin production and producing a feeling of satiety. It is often used to treat obesity and type 2 diabetes and is given once a day.

The next morning, the subjects were given a learning task that allowed the researchers to measure how well associative learning works. They found that the ability to associate sensory stimuli was less pronounced in participants with obesity than in those of normal weight and that brain activity was reduced in the areas encoding this learning behavior.

After just one dose of liraglutide, participants with obesity no longer showed these impairments, and no difference in brain activity was seen between participants with normal weight and obesity. In other words, the drug returned the brain activity to the state of normal-weight subjects.

“These findings are of fundamental importance. We show here that basic behaviors such as associative learning depend not only on external environmental conditions but also on the body’s metabolic state. So, whether someone is overweight or not also determines how the brain learns to associate sensory signals and what motivation is generated. The normalization we achieved with the drug in subjects with obesity, therefore, fits with studies showing that these drugs restore a normal feeling of satiety, causing people to eat less and therefore lose weight,” says study leader Marc Tittgemeyer from the Max Planck Institute for Metabolism Research.

“While it is encouraging that available drugs have a positive effect on brain activity in obesity, it is alarming that changes in brain performance occur even in young people with obesity without other medical conditions. Obesity prevention should play a much greater role in our healthcare system in the future. Lifelong medication is the less preferred option in comparison to primary prevention of obesity and associated complications,” says Ruth Hanßen, first author of the study and a physician at the University Hospital of Cologne.

Reference: “Liraglutide restores impaired associative learning in individuals with obesity” by Ruth Hanssen, Lionel Rigoux, Bojana Kuzmanovic, Sandra Iglesias, Alina C. Kretschmer, Marc Schlamann, Kerstin Albus, Sharmili Edwin Thanarajah, Tamara Sitnikow, Corina Melzer, Oliver A. Cornely, Jens C. Brüning and Marc Tittgemeyer, 17 August 2023, Nature Metabolism.
DOI: 10.1038/s42255-023-00859-y

The study was conducted at the Max Planck Institute for Metabolism Research and supported by the CECAD Cluster of Excellence for Ageing Research at the University of Cologne and the University Hospital of Cologne.

1 Comment on "Not Just Weight Loss: The Unexpected Brain Benefits of an Anti-Obesity Drug"

  1. Any study including fat persons needs to account for a common CONFOUNDING factor -previous diets, up and down weight, and any other weight interventions. I’d bet the rent that those who have not lost and regained weight will be very much more similar to the slender people.
    If this proves valid, then diets, not obesity, are the culprits.

Leave a comment

Email address is optional. If provided, your email will not be published or shared.